5-(4-ethanoylphenoxy)pentanoic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-(4-ethanoylphenoxy)pentanoic acid
• 英文别名: 5-(4-ACETYLPHENOXY)PENTANOIC ACID
• 化学式: C₁₃H₁₆O₄
• mdl: MFCD11192928
• 分子量: 236.268
• InChiKey: CROYTYSPZWBOAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-溴戊酸 在 氢气 sodium hydroxide 、 sodium methylate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 5-(4-ethanoylphenoxy)pentanoic acid
  参考文献：
  名称：

  基于苯乙酮的接头，可在Multipin™载体上固相合成仲酰胺和磺酰胺

  摘要：

  已经开发了用于合成仲酰胺和磺酰胺的新的和简单的接头。该申请是基于连接基的苯乙酮亚基与包括脂肪族和芳香族胺在内的各种伯胺之间的还原胺化反应。在温和的酸性条件（20％TFA / DCM）下进行裂解，以良好的产率和纯度释放产物。

  DOI：

  10.1016/s0040-4039(99)00426-8

文献信息

• Novel benzylpiperidine compound
  申请人：——

  公开号：US20040158071A1

  公开（公告）日：2004-08-12

  The object of the present invention is to provide a compound having a treatment effect based on a chemokine inhibitory activity, which is satisfactory as a pharmaceutical product for oral administration. The present inventors have found that the following benzylpiperidine derivative (the formula (1)) has a chemokine inhibitory activity. Further intensive studies have resulted in successful enhancement of the chemokine inhibitory activity and stability in blood of the present compound, as well as the completion of the present invention. 1 wherein each symbol is as defined in the specification.

  本发明的目的是提供一种具有基于趋化因子抑制活性的治疗效果的化合物，作为口服药物而言，具有令人满意的药物品质。本发明人发现以下苯基哌啶衍生物（式（1））具有趋化因子抑制活性。进一步的深入研究成功增强了该化合物的趋化因子抑制活性和血液稳定性，从而完成了本发明。式中每个符号如说明书中所定义。
• NOVEL BENZYLPIPERIDINE COMPOUND
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1389616A1

  公开（公告）日：2004-02-18

  The object of the present invention is to provide a compound having a treatment effect based on a chemokine inhibitory activity, which is satisfactory as a pharmaceutical product for oral administration. The present inventors have found that the following benzylpiperidine derivative (the formula (1)) has a chemokine inhibitory activity. Further intensive studies have resulted in successful enhancement of the chemokine inhibitory activity and stability in blood of the present compound, as well as the completion of the present invention. wherein each symbol is as defined in the specification.

  本发明的目的是提供一种具有基于趋化因子抑制活性的治疗效果的化合物，该化合物作为口服药物是令人满意的。 本发明者发现以下苄基哌啶衍生物（式（1））具有趋化因子抑制活性。通过进一步深入研究，成功地提高了本化合物的趋化因子抑制活性和在血液中的稳定性，并完成了本发明。 其中各符号如说明书中所定义。
• Bi-functional complexes and methods for making and using such complexes
  申请人：Gouliaev Alex Haahr

  公开号：US11225655B2

  公开（公告）日：2022-01-18

  The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.

  本发明涉及一种合成双功能复合物的方法，该复合物包括分子部分和识别分子部分的识别寡核苷酸部分。根据本发明的合成方法的一部分优选在一种或多种有机溶剂中进行，此时包含可选保护标签或寡核苷酸标识符的新生双功能复合物与固体支持物相连接，合成方法的另一部分优选在适合于将寡核苷酸标签酶加到溶液中的新生双功能复合物的条件下进行。
• 3,4-Dihalobenzylpiperidine derivatives and their medical use
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1389616B1

  公开（公告）日：2011-07-27
• Discovery of gemfibrozil analogues that activate PPARα and enhance the expression of gene CPT1A involved in fatty acids catabolism
  作者：Barbara De Filippis、Antonella Giancristofaro、Alessandra Ammazzalorso、Alessandra D’Angelo、Marialuigia Fantacuzzi、Letizia Giampietro、Cristina Maccallini、Michele Petruzzelli、Rosa Amoroso

  DOI：10.1016/j.ejmech.2011.08.022

  日期：2011.10

  A new series of gemfibrozil analogues conjugated with alpha-asarone, trans-stilbene, chalcone, and their bioisosteric modifications were synthesized and evaluated to develop PPAR alpha agonists. In this attempt, we have removed the methyls on the phenyl ring of gemfibrozil and introduced the above scaffolds in para position synthesizing two series of derivatives, keeping the dimethylpentanoic skeleton of gemfibrozil unaltered or demethylated. Four compounds exhibited good activation of the PPAR alpha receptor and were also screened for their activity on PPAR alpha-regulated gene CPT1A. (C) 2011 Elsevier Masson SAS. All rights reserved.